Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: A phenomenological investigation
Elisa Liberati, Hv Curran, Peter Fonagy, Henry Clements, Alessandra Lemma, Rosalind McAlpine, David Nutt, Anne Katrin Schlag, Sunjeev K. Kamboj
PLoS One June 18, 2026 DOI: 10.1371/journal.pone.0350728 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative mechanistic study Open-label Peer reviewed |
|---|---|
| Sample size | 25 |
| Population | Experienced psychodynamically trained psychotherapists |
| Dose | 80-120 mg, oral, two doses separated by at least 1 week |
| Duration | Not explicitly stated (two doses separated by ≥1 week, plus follow-up interviews) |
| Measures | reflective functioning and related constructs (standardized measures), phenomenological interviews, reflective journals |
| Topics | MDMA |
| Keywords | Grounded theory Interpretative phenomenological analysis Thematic analysis Qualitative research Experiential learning Underpinning Phenomenology philosophy Critical appraisal Psychotherapist Clinical psychology Qualitative property Transformative learning Reflexivity Action physics Psychological theory Psychoanalytic theory Psychological intervention |
| Key findings | The primary output will be a theoretically grounded model of MDMA's psychological mechanisms of action, intended to inform novel treatment models. |
Abstract
Introduction: Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) is a potentially transformative intervention for post-traumatic stress disorder (PTSD). Despite encouraging Phase III trial results, the psychological mechanisms underpinning MDMA's therapeutic effects remain insufficiently understood. Existing research on MDMA has emphasised neurobiological processes but has not adequately incorporated subjective, relational, and experiential processes that are likely to be central to optimising psychedelic-assisted treatments. In the absence of an established clinical psychological theory of MDMA-AP, qualitative approaches can support theory development to refine and optimise MDMA-AP, and identify cross-diagnostic change processes that may broaden its therapeutic scope.
Materials and Methods: Approximately 25 experienced psychodynamically trained psychotherapists will receive two doses of MDMA (80-120 mg, oral), separated by ≥1 week, under controlled research conditions in an open-label, qualitative mechanistic study. Clinician-participants will complete baseline interviews examining beliefs and attitudes toward MDMA-AP, brief phenomenological interviews during MDMA sessions, in-depth phenomenological and theory-oriented follow-up interviews examining experience and understandings of MDMA-associated change processes, and daily reflective journals between dosing sessions. Additional standardised measures will assess reflective functioning and related constructs. Qualitative data will be analysed using phenomenological and thematic approaches, and grounded theory-inspired techniques will be used to develop a theoretically coherent model of MDMA's psychological mechanisms of action grounded in the full dataset.
Discussion: In this study of MDMA's potential mechanisms-of-action, we treat psychotherapists as expert observers of their own psychological processes. By examining first-hand experience in participants selected for their well-developed capacity for self-reflection, meta-awareness, and advanced theoretical and clinical frameworks for understanding mental phenomena, psychopathology, and psychological treatment, we anticipate generating novel insights into MDMA's therapeutic mechanisms-of-action. The primary study output will be a theoretically grounded model of MDMA's psychological mechanisms of action, intended to inform novel treatment models amenable to future experimental evaluation. The study also offers a transferable framework for qualitative mechanistic investigations of psychedelic compounds, supporting the development of integrative and evidence-based models of psychedelic therapy.
Comparable studies
Other experimental studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin | 2000 | Experimental study | |
| Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Rat brain | 1988 | Experimental study | |
| The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Human platelet plasma membrane vesicles and bovine adrenal chromaffin granule membrane... | 1992 | Laboratory study | |
| Oxytocin-dependent reopening of a social reward learning critical period with MDMA | 2019 | Experimental study | |
| Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes Rat whole brain synaptosomes | 1982 | Experimental study |
Citations in the library
Cites 13
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) PLoS One August 31, 2010
- Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology July 11, 2019
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies CNS Drugs August 17, 2020
and 8 more in the library